Industry & Regulation

BASF Weighs Renewed €11.18 Billion-Plus Bid for Evonik

BASF Prepares New Takeover Offer for Evonik
tasukaran / pixabay

BASF is preparing a second takeover offer for Evonik Industries after the specialty chemicals maker rejected an initial proposal valued at €11.18 billion — €24 per share — according to Bloomberg. A revised bid could land within days, though its value has not been disclosed.

The news moved markets immediately. Evonik shares rose roughly 4% on reports of the renewed interest. BASF declined to comment, and no agreement has been reached.

Who is BASF talking to before it bids again?

Before tabling a new offer, BASF is consulting the stakeholders whose support any deal would need:

  • The state government of North Rhine-Westphalia, where much of Germany's chemicals manufacturing sits
  • Members of parliament
  • The RAG Foundation, Evonik's largest shareholder

That sequence matters. A hostile approach against an entrenched anchor shareholder and a state government would be difficult to execute. Sounding them out first signals BASF wants a negotiated path.

Evonik rejected the earlier €24-per-share offer on the grounds that it was insufficient. BASF has reportedly indicated it would honor and expand existing commitments on employment and manufacturing sites — a direct response to restructuring fears that typically accompany consolidation of this scale.

What does this change for cosmetics and personal care?

The two companies are major suppliers of ingredients and technologies used in cosmetics and personal care manufacturing. A combined BASF-Evonik would represent significant consolidation in the European specialty chemicals industry, and the practical effects would run through three channels:

  • Supplier relationships. Cosmetics manufacturers sourcing from both companies could face renegotiated contracts, consolidated sales forces and changed pricing dynamics as overlapping portfolios merge.
  • R&D capabilities. Pooled research in specialty ingredients could accelerate innovation — or concentrate it in a single negotiating counterparty.
  • Ingredient sourcing strategies. Formulators that deliberately dual-source between BASF and Evonik to hedge supply risk would lose that option for overlapping ingredients.

Put plainly: if you formulate with specialty ingredients from either supplier, your counterparty landscape could shrink from two majors to one.

What stands in the way?

Plenty. Any merger would face regulatory scrutiny, and the report flags three friction points explicitly: employment, manufacturing operations and market competition. European competition authorities would examine overlap in specialty chemical lines, including those serving personal care. The employment and site commitments BASF is reportedly prepared to expand exist precisely because those concerns are live.

The RAG Foundation's position is the swing factor. As Evonik's largest shareholder, it effectively holds a veto over any offer BASF can't force through. Its view on a revised price — and on the durability of site and jobs pledges — will likely determine whether round two goes further than round one.

Where things stand

For now: one rejected €11.18 billion bid, a reported second offer in preparation, a 4% share-price pop at the target, and silence from the bidder. The next concrete signal will be the terms of the new offer — its per-share price versus the rejected €24, and how far the employment and site commitments stretch. If BASF prices the political and shareholder concerns into the bid, a merger that reshapes ingredient supply for the cosmetics industry moves from speculation to negotiation.

Source: globalcosmeticsnews.com

Share this article:

Olivia Hart

Show full bio

News editor covering technology and product news in Clinical dermatology, inflammatory skin disease and biologics at Derm Field.

More from Olivia Hart →

Related articles

« Previous articleNext article »